For patients with luminal A, luminal B, HER2, and triple-negative subtypes of breast cancer, the 5-year OS rates were 92.6%, 88.4%, 83.6%, and 82.9%, respectively (Fig. 1c); the 5-year CSS rates were 93.2%, 89.1%, 85.4%, and 83.5%, respectively (Fig. 1d). The gene discussed is ERBB2; the disease is breast carcinoma.